Analysis of biocontrol product registration applications submitted to Brazil’s Ministry of Agriculture, Livestock and Food Supply (MAPA) in 2025 reveals a profound market shift. Biotech firms are increasingly seeking genetic identification services for exclusive microbial strains, signaling a transition toward differentiated, genetically defined solutions.
While traditional microorganisms remain dominant in registration volumes, emerging trends indicate the industry is entering an innovation phase marked by exclusive strain development and advanced genetic analysis. As the bio-inputs market matures, this shift will reshape corporate competitive positioning.
Classic Fungi Lead Registration Volumes
Data shows three fungal species account for over half of current registration applications. Beauveria bassiana leads with a 24.7% share, followed by Trichoderma harzianum at 18.3% and Metarhizium anisopliae at 11.8%. These microorganisms form the backbone of Brazil’s biocontrol system for pests and diseases.
Beauveria bassiana and Metarhizium anisopliae are highly effective microbial insecticides, widely used in agriculture to control whiteflies, leafhoppers and coffee berry borers. Trichoderma harzianum serves dual roles as a microbial fungicide and plant growth promoter, enhancing root colonization and maintaining soil balance.
The dominance of these classic strains stems from their proven field performance and regulatory familiarity. Compared to novel microorganisms requiring extensive efficacy data and toxicological evaluations, they can enter the market more rapidly.
Surging Demand for Genetic Identification
Despite ongoing market reliance on established microorganisms, GoGenetic has observed a clear shift in demand. “We’ve seen a significant surge in requests for genetic identification of specific, unique microbial strains and exclusive rights to solutions in recent months,” noted the company’s CEO. “In R&D, enterprises continuously pursue new technologies, microorganisms and exclusive strains to develop differentiated products.”
This trend reflects a strategic realization: in an increasingly mature bio-market, competitive advantage increasingly stems from exclusive microbial genetics rather than commodity formulations accessible to all enterprises. The momentum is driving greater investment in strain isolation, identification and intellectual property protection.
Registration Favors Broad-Spectrum Strategy
Registration applications most commonly target economically damaging pests and diseases, including whiteflies, Sclerotinia sclerotiorum, Bemisia tabaci and southern blight. The most prevalent regulatory description—“suitable for all crops with target organisms”—indicates enterprises are prioritizing broad-spectrum products that serve diverse production systems with a single formulation.
This strategy maximizes market coverage while streamlining regulatory processes. Broad-spectrum claims enable commercial application across multiple crops without meeting crop-specific registration requirements, avoiding market entry delays and reducing compliance costs.
Future Tilt Toward Personalization
Technological advancements and maturing biotechnology are propelling bio-inputs into a new innovation cycle. “The future core of the industry lies in genetics and personalization,” said Tadra, GoGenetic’s CEO. “Enterprises aim to deeply understand the microorganisms they use and secure exclusive rights to strains—this is the only path to developing more efficient, stable and sustainable products.”
The executive predicts accelerating change: “Trends now limited to R&D will become industry norms in the short term. We will see a significant increase in registrations of new microorganisms and bio-complexes, designed not only to control specific pests and diseases but also to restore soil microbial balance.”
The evolution from single-microbe formulations to microbial consortia represents an upgrade in bio-product development complexity. This requires advanced genetic identification technologies to ensure strain compatibility, stability and complementary mechanisms of action—an capability that will give enterprises with advanced R&D infrastructure an edge over those relying on conventional microorganisms.
Impact on Competitive Landscape
Brazil’s bio-inputs market is projected to exceed $3 billion in size over the next decade, attracting domestic and international enterprises. Against this backdrop, the shift toward genetically defined exclusive strains will reshape the competitive landscape. In an increasingly crowded market, product performance—not price—is becoming the key determinant of market share. Enterprises building intellectual property barriers around novel strains or microbial combinations are poised to gain differentiated competitive advantages.
As Brazil’s bio-inputs regulations continue to improve, enterprises leading in genetic identification and exclusive strain R&D may establish insurmountable technical and commercial barriers. This could drive a restructuring of the market around innovation leaders.
